- Home
- AII vs VNDA Comparison
AII vs VNDA Comparison
Compare AII & VNDA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | AII | VNDA |
|---|---|---|
| Founded | 2006 | 2002 |
| Country | United States | United States |
| Employees | 313 | N/A |
| Industry | Property-Casualty Insurers | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 333.2M | 387.9M |
| IPO Year | N/A | 2005 |
Fundamental Metrics
Financial Performance| Metric | AII | VNDA |
|---|---|---|
| Price | $16.61 | $6.38 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 7 | 5 |
| Target Price | ★ $26.33 | $14.90 |
| AVG Volume (30 Days) | 78.9K | ★ 1.1M |
| Earning Date | 05-12-2026 | 05-06-2026 |
| Dividend Yield | ★ 5.27% | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $216,105,000.00 |
| Revenue This Year | $35.92 | $21.35 |
| Revenue Next Year | $17.74 | $37.40 |
| P/E Ratio | $4.12 | ★ N/A |
| Revenue Growth | N/A | ★ 8.72 |
| 52 Week Low | $15.78 | $4.14 |
| 52 Week High | $26.36 | $9.91 |
Technical Indicators
Market Signals| Indicator | AII | VNDA |
|---|---|---|
| Relative Strength Index (RSI) | 34.94 | 44.89 |
| Support Level | $16.28 | $5.85 |
| Resistance Level | $19.89 | $7.76 |
| Average True Range (ATR) | 0.61 | 0.24 |
| MACD | -0.09 | 0.05 |
| Stochastic Oscillator | 9.36 | 53.64 |
Price Performance
Historical ComparisonAbout AII American Integrity Insurance Group Inc.
American Integrity Insurance Group Inc is engaged in the property and casualty insurance business. It provides personal residential property insurance for single-family homeowners and condominium owners as well as coverage for vacant dwellings and investment properties, predominantly in Florida. The Company's property and casualty insurance is currently offered in Florida, North Carolina, South Carolina, and Georgia.
About VNDA Vanda Pharmaceuticals Inc.
Vanda Pharmaceuticals Inc is a biopharmaceutical company engaged in the development and commercialization of therapies to address high unmet medical needs and improve the lives of patients. Its commercial portfolio comprises three products; HETLIOZ for the treatment of Non-24-Hour Sleep-Wake Disorder (Non-24) & nighttime sleep disturbances in Smith-Magenis Syndrome (SMS); Fanapt for the treatment of schizophrenia; and PONVORY. Its other products include ASO Molecules, VQW-765, Tradipitant, and VTR-297. The maximum of revenue is derived from the Fanapt product sales. Geographically, the company sells its product predominantly in the United States, and also in Israel, Europe, and Canada.